Head to Head Contrast: Cytocore (OTCMKTS:MDIT) & AtriCure (OTCMKTS:ATRC)

AtriCure (NASDAQ:ATRC) and Cytocore (OTCMKTS:MDIT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Volatility & Risk

AtriCure has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Cytocore has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AtriCure and Cytocore, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AtriCure 0 0 7 0 3.00
Cytocore 0 0 0 0 N/A

AtriCure presently has a consensus price target of $52.71, indicating a potential upside of 36.85%. Given AtriCure’s higher possible upside, research analysts plainly believe AtriCure is more favorable than Cytocore.

Earnings & Valuation

This table compares AtriCure and Cytocore’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AtriCure $230.81 million 7.50 -$35.19 million ($1.07) -36.00
Cytocore $6.81 million 0.04 -$6.81 million N/A N/A

Cytocore has lower revenue, but higher earnings than AtriCure.

Profitability

This table compares AtriCure and Cytocore’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AtriCure -23.64% -19.55% -9.56%
Cytocore N/A N/A N/A

Insider & Institutional Ownership

93.5% of AtriCure shares are owned by institutional investors. Comparatively, 0.0% of Cytocore shares are owned by institutional investors. 5.8% of AtriCure shares are owned by company insiders. Comparatively, 85.4% of Cytocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cytocore beats AtriCure on 6 of the 11 factors compared between the two stocks.

AtriCure Company Profile

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Cytocore Company Profile

MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.